I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
B002 in Patients With HER2-positive Breast Cancer
To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.
monoclonal antibodies
metastasis
primary tumor
cancer
bone metastases
- 0 views
- 19 Feb, 2024